US5698579A
(en)
*
|
1993-07-02 |
1997-12-16 |
Celgene Corporation |
Cyclic amides
|
US5703098A
(en)
*
|
1994-12-30 |
1997-12-30 |
Celgene Corporation |
Immunotherapeutic imides/amides
|
US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
US6518281B2
(en)
*
|
1995-08-29 |
2003-02-11 |
Celgene Corporation |
Immunotherapeutic agents
|
US5728844A
(en)
*
|
1995-08-29 |
1998-03-17 |
Celgene Corporation |
Immunotherapeutic agents
|
EP1361210B1
(en)
*
|
1996-08-12 |
2008-12-24 |
Celgene Corporation |
Novel immunotherapeutic agents and their use in the reduction of cytokine levels
|
WO1998007421A1
(fr)
|
1996-08-16 |
1998-02-26 |
Ishihara Sangyo Kaisha, Ltd. |
Composition medicinale
|
ES2262072T3
(es)
|
1998-04-28 |
2006-11-16 |
Elbion Ag |
Derivados de indol y su utilizacion como inhibidores de la fosfodiesterasa 4.
|
DE19818964A1
(de)
*
|
1998-04-28 |
1999-11-04 |
Dresden Arzneimittel |
Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
|
US6838436B1
(en)
|
1998-07-10 |
2005-01-04 |
Osteoscreen Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6902721B1
(en)
|
1998-07-10 |
2005-06-07 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6462019B1
(en)
|
1998-07-10 |
2002-10-08 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity and production for stimulating bone growth
|
US6020358A
(en)
*
|
1998-10-30 |
2000-02-01 |
Celgene Corporation |
Substituted phenethylsulfones and method of reducing TNFα levels
|
KR100701904B1
(ko)
|
1999-08-21 |
2007-04-02 |
알타나 파마 아게 |
Pde 억제제 및 베타 2 아드레날린수용체 작동제의상승적 조합
|
US6667316B1
(en)
*
|
1999-11-12 |
2003-12-23 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
US6808902B1
(en)
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
US7182953B2
(en)
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
US6326388B1
(en)
|
1999-12-21 |
2001-12-04 |
Celgene Corporation |
Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
|
US6699899B1
(en)
*
|
1999-12-21 |
2004-03-02 |
Celgene Corporation |
Substituted acylhydroxamic acids and method of reducing TNFα levels
|
EP2258689A1
(en)
|
2000-03-16 |
2010-12-08 |
Biolipox AB |
Benzylated PDE4 inhibitors
|
US8030343B2
(en)
|
2000-06-08 |
2011-10-04 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
WO2002068414A2
(en)
|
2001-02-27 |
2002-09-06 |
The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Analogs of thalidomide as potential angiogenesis inhibitors
|
US7491634B2
(en)
*
|
2006-04-28 |
2009-02-17 |
Asm International N.V. |
Methods for forming roughened surfaces and applications thereof
|
CA2447618A1
(en)
*
|
2001-05-23 |
2002-11-28 |
Tanabe Seiyaku Co., Ltd. |
A composition for regenerative treatment of cartilage disease
|
CN1520313A
(zh)
|
2001-05-23 |
2004-08-11 |
������ҩ��ʽ���� |
一种加速骨折愈合的组合物
|
KR20040023630A
(ko)
|
2001-06-26 |
2004-03-18 |
아브게닉스, 인크. |
Opgl에 결합하는 항체
|
TWI221838B
(en)
|
2001-08-09 |
2004-10-11 |
Tanabe Seiyaku Co |
Pyrazinoisoquinoline compound or naphthalene compound
|
US7276529B2
(en)
*
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US6962940B2
(en)
*
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
US7208516B2
(en)
*
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
CA2481385A1
(en)
*
|
2002-04-12 |
2003-10-23 |
Celgene Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
US7498171B2
(en)
*
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
JP2005536189A
(ja)
*
|
2002-04-12 |
2005-12-02 |
セルジーン・コーポレーション |
血管新生のモジュレーターの同定方法、それにより見出された化合物および該化合物を使用する治療方法
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
CA2486141A1
(en)
*
|
2002-05-17 |
2003-11-27 |
Celgene Corporation |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
US9415102B2
(en)
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
US20040115194A1
(en)
*
|
2002-09-06 |
2004-06-17 |
Yi Wang |
Method of treatment of asthma using antibodies to complement component C5
|
WO2004034962A2
(en)
*
|
2002-10-15 |
2004-04-29 |
Celgene Corporation |
Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
|
US20040087558A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
US7776907B2
(en)
*
|
2002-10-31 |
2010-08-17 |
Celgene Corporation |
Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
TW200501945A
(en)
|
2002-11-06 |
2005-01-16 |
Celgene Corp |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
WO2004043336A2
(en)
*
|
2002-11-06 |
2004-05-27 |
Celgene Corporation |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
|
WO2004045597A1
(en)
*
|
2002-11-18 |
2004-06-03 |
Celgene Corporation |
Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
|
MXPA05005161A
(es)
*
|
2002-11-18 |
2005-07-22 |
Celgene Corp |
Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida.
|
US20060079540A1
(en)
*
|
2002-11-27 |
2006-04-13 |
Altana Pharma Ag |
Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
|
CN1802353A
(zh)
|
2002-12-30 |
2006-07-12 |
细胞基因公司 |
氟烷氧基取代的1,3-二氢-异吲哚化合物及其药物用途
|
US7283048B2
(en)
*
|
2003-02-03 |
2007-10-16 |
Ingrid, Inc. |
Multi-level meshed security network
|
US20040175382A1
(en)
*
|
2003-03-06 |
2004-09-09 |
Schafer Peter H. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
JP4943845B2
(ja)
|
2003-09-17 |
2012-05-30 |
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
サリドマイド類似体
|
US8952895B2
(en)
|
2011-06-03 |
2015-02-10 |
Apple Inc. |
Motion-based device operations
|
US20050142104A1
(en)
*
|
2003-11-06 |
2005-06-30 |
Zeldis Jerome B. |
Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
|
AU2004293443A1
(en)
|
2003-11-19 |
2005-06-09 |
Signal Pharmaceuticals, Llc. |
Indazole Compounds and methods of use thereof as protein kinase inhibitors
|
BRPI0418743A
(pt)
*
|
2004-04-14 |
2007-09-18 |
Celgene Corp |
métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
|
CA2563377A1
(en)
*
|
2004-04-23 |
2005-11-03 |
Celgene Corporation |
Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
|
US7244759B2
(en)
|
2004-07-28 |
2007-07-17 |
Celgene Corporation |
Isoindoline compounds and methods of making and using the same
|
US20070190070A1
(en)
*
|
2004-09-03 |
2007-08-16 |
Zeldis Jerome B |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
|
BRPI0514857A
(pt)
|
2004-09-03 |
2008-05-06 |
Celgene Corp |
composto ou um sal, solvato ou hidrato farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para inibir a angiogênese, para inibir ou reduzir a polimerização da tubulina ou a estabilidade da tubulina em uma célula, para inibir a atividade de pde4 em uma célula, para inibir atividade do fator-alfa de necrose de tumor (tnf-alfa) em uma célula, para tratar ou melhorar um distúrbio inflamatório, para tratar ou melhorar cáncer, para inibir a proliferação de célula cancerosa, para marcar, bloquear ou destruir a função de vasculatura tumoral, para marcar, bloquear ou destruir o endotélio de vasos tumor, para marcar, bloquear ou destruir a função de vasculatura tumoral e inibir a angiogênese em um tumor e para tratar ou melhorar um distúrbio do sistema nervoso central
|
JP2008518924A
(ja)
*
|
2004-10-28 |
2008-06-05 |
セルジーン・コーポレーション |
中枢神経系損傷の治療及び管理のためのpde4モジュレータを使用する方法及び組成物
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
CN101186612B
(zh)
|
2006-11-15 |
2012-10-03 |
天津和美生物技术有限公司 |
可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
|
EP2268279A1
(en)
*
|
2008-03-24 |
2011-01-05 |
Celgene Corporation |
Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl¨-3-oxoisoindoline-4-yl}carboxamide
|
MX353900B
(es)
|
2008-11-07 |
2018-02-01 |
Massachusetts Inst Technology |
Lipidoides de aminoalcohol y usos de los mismos.
|
EP2818164A1
(en)
|
2009-02-10 |
2014-12-31 |
Celgene Corporation |
Methods of using and compositions comprising PDE4-modulators for treatment, prevention and management of tuberculosis
|
EP2516395A1
(en)
*
|
2009-12-22 |
2012-10-31 |
Celgene Corporation |
(methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
|
WO2011127019A2
(en)
|
2010-04-07 |
2011-10-13 |
Celgene Corporation |
Methods for treating respiratory viral infection
|
US20110318741A1
(en)
|
2010-06-15 |
2011-12-29 |
Schafer Peter H |
Biomarkers for the treatment of psoriasis
|
EP2609135A4
(en)
|
2010-08-26 |
2015-05-20 |
Massachusetts Inst Technology |
POLY (BETA-AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF
|
PL2691443T3
(pl)
|
2011-03-28 |
2021-08-30 |
Massachusetts Institute Of Technology |
Sprzężone lipomery i ich zastosowania
|
CA3119789A1
(en)
|
2011-10-27 |
2013-05-02 |
Massachusetts Institute Of Technology |
Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres
|
US8927725B2
(en)
|
2011-12-02 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thio compounds
|
EP2882706A1
(en)
|
2012-08-13 |
2015-06-17 |
Massachusetts Institute of Technology |
Amine-containing lipidoids and uses thereof
|
US9315472B2
(en)
|
2013-05-01 |
2016-04-19 |
Massachusetts Institute Of Technology |
1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
|
US20170087129A1
(en)
|
2014-05-16 |
2017-03-30 |
Celgene Corporation |
Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
|
EP3148552B1
(en)
|
2014-05-30 |
2019-07-31 |
Translate Bio, Inc. |
Biodegradable lipids for delivery of nucleic acids
|
MX2016014384A
(es)
|
2014-06-23 |
2017-01-20 |
Celgene Corp |
Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
|
CN111588695A
(zh)
|
2014-06-24 |
2020-08-28 |
川斯勒佰尔公司 |
用于递送核酸的立体化学富集组合物
|
US9840479B2
(en)
|
2014-07-02 |
2017-12-12 |
Massachusetts Institute Of Technology |
Polyamine-fatty acid derived lipidoids and uses thereof
|
AR103598A1
(es)
|
2015-02-02 |
2017-05-24 |
Forma Therapeutics Inc |
Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac
|
AU2016215432B2
(en)
|
2015-02-02 |
2020-07-30 |
Valo Early Discovery, Inc. |
3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
|
JP6800410B2
(ja)
|
2015-06-19 |
2020-12-16 |
マサチューセッツ インスティテュート オブ テクノロジー |
アルケニル置換2,5−ピペラジンジオン、および、対象または細胞に剤を送達するための組成物におけるそれらの使用
|
WO2017070291A1
(en)
|
2015-10-21 |
2017-04-27 |
Celgene Corporation |
Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris)
|
EP3165224A1
(en)
|
2015-11-09 |
2017-05-10 |
Albert-Ludwigs-Universität Freiburg |
Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
|
WO2017089347A1
(en)
|
2015-11-25 |
2017-06-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
|
US10555935B2
(en)
|
2016-06-17 |
2020-02-11 |
Forma Therapeutics, Inc. |
2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
|
US10357493B2
(en)
|
2017-03-10 |
2019-07-23 |
Selenity Therapeutics (Bermuda), Ltd. |
Metalloenzyme inhibitor compounds
|
CN110746376B
(zh)
*
|
2018-07-22 |
2024-04-30 |
上海星叶医药科技有限公司 |
苯并异硒唑酮胺类化合物及其制备方法和用途
|